 The main objective of this prospective clinical trial is to compare pharmacokinetics and safety and tolerability of a standard dose 400 mg with an escalated dose 600 mg; 800 mg of moxifloxacin MFX. This clinical trial will provide important safety information on MFX in a higher dosage in TB patients. 